[go: up one dir, main page]

HK1039059A1 - Methods of downmodulating the immune response to therapeutic proteins - Google Patents

Methods of downmodulating the immune response to therapeutic proteins Download PDF

Info

Publication number
HK1039059A1
HK1039059A1 HK02100157.7A HK02100157A HK1039059A1 HK 1039059 A1 HK1039059 A1 HK 1039059A1 HK 02100157 A HK02100157 A HK 02100157A HK 1039059 A1 HK1039059 A1 HK 1039059A1
Authority
HK
Hong Kong
Prior art keywords
methods
therapeutic proteins
downmodulating
immune response
agents
Prior art date
Application number
HK02100157.7A
Other languages
Chinese (zh)
Inventor
Qian Jiahua
W Hoyer Leon
Collins Mary
S Gray Gary
Original Assignee
Genetics Institute, Llc
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc, American Red Cross filed Critical Genetics Institute, Llc
Publication of HK1039059A1 publication Critical patent/HK1039059A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for treating a hemostatic disorder using agents which promote hemostasis and agents which inhibit a costimulatory signal in a T cell are provided. The instant compositions and methods enable the treatment of hemostatic disorders using foreign therapeutic proteins, while downmodulating immune responses to the therapeutic proteins.
HK02100157.7A 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins HK1039059A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158,178 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (1)

Publication Number Publication Date
HK1039059A1 true HK1039059A1 (en) 2002-04-12

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100157.7A HK1039059A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (en)
JP (1) JP2002526455A (en)
KR (1) KR20010085830A (en)
CN (1) CN1331602A (en)
AU (1) AU761206B2 (en)
BR (1) BR9913991A (en)
CA (1) CA2343916A1 (en)
CZ (1) CZ20011021A3 (en)
EA (1) EA005236B1 (en)
HK (1) HK1039059A1 (en)
HU (1) HUP0103960A3 (en)
IL (1) IL142069A0 (en)
LT (1) LT4920B (en)
LV (1) LV12768B (en)
MX (1) MXPA01002898A (en)
NO (1) NO20011412L (en)
NZ (1) NZ511034A (en)
PL (1) PL346796A1 (en)
SI (1) SI20626A (en)
WO (1) WO2000016801A1 (en)
ZA (1) ZA200103156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU2001261735B2 (en) * 2000-05-19 2006-09-21 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US7040139B2 (en) * 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
JPH0788399B2 (en) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド Novel procoagulant protein
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (en) 1990-02-05 1994-09-02 Tm Innovation PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
KR100238712B1 (en) 1991-06-27 2000-01-15 스티븐 비. 데이비스 CTIA4 Receptor, Associated Protein Containing It and Uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU3161695A (en) * 1994-08-19 1996-03-14 Novo Nordisk A/S A method of treating a patient with a biologically active compound
JPH10507758A (en) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド Gene therapy with simultaneous administration of adenovirus and immunosuppressive drugs
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co Uses of soluble ligands that interact with gp39, cd40, b7, ctla4 and/or cd28 for preparing pharmaceutical compositions
KR20000070035A (en) * 1997-01-10 2000-11-25 아스트루 마이클 제이 Methods Of Therapeutic Administration of Anti-CD40L Compounds
SK285962B6 (en) * 1997-06-20 2007-12-06 Biogen Idec Ma Inc. Use of a CD40:CD154 binding interruptor for attenuating severity of exogenous protein inhibitor syndrome
US20110112786A1 (en) 2009-11-06 2011-05-12 Hexagon Metrology Ab Cmm with improved sensors

Also Published As

Publication number Publication date
EA005236B1 (en) 2004-12-30
HUP0103960A3 (en) 2003-09-29
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (en) 2002-02-28
MXPA01002898A (en) 2002-06-04
LV12768A (en) 2001-12-20
IL142069A0 (en) 2002-03-10
ZA200103156B (en) 2002-07-18
AU6057899A (en) 2000-04-10
WO2000016801A9 (en) 2000-10-26
NO20011412D0 (en) 2001-03-20
CA2343916A1 (en) 2000-03-30
SI20626A (en) 2002-02-28
KR20010085830A (en) 2001-09-07
WO2000016801A1 (en) 2000-03-30
JP2002526455A (en) 2002-08-20
PL346796A1 (en) 2002-02-25
CZ20011021A3 (en) 2001-10-17
EA200100385A1 (en) 2001-10-22
LT4920B (en) 2002-06-25
CN1331602A (en) 2002-01-16
NO20011412L (en) 2001-05-16
NZ511034A (en) 2004-03-26
BR9913991A (en) 2001-07-03
LV12768B (en) 2002-06-20
AU761206B2 (en) 2003-05-29
LT2001045A (en) 2002-01-25

Similar Documents

Publication Publication Date Title
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
ATE257390T1 (en) USE OF A BPI PROTEIN PRODUCT AS AN ANTITHRBOTIC AGENT
WO2002015920A3 (en) Treatment of hyperproliferative diseases
EP2123282A3 (en) Immunemodulating oligosaccharides
WO2002049593A3 (en) Use of dna repair enzymes as mmp-1 inhibitors
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO1997040072A3 (en) Adam proteins and uses thereof
AU4229200A (en) Methods and compositions for treating dermatological disorders with fruit extracts
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO1996040743A3 (en) Inhibitors of factor xa
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
BG101126A (en) The use of muramylpeptide compounds
HK1039059A1 (en) Methods of downmodulating the immune response to therapeutic proteins
WO1996013498A3 (en) L-erythrosyl nucleosides
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
AU4823999A (en) Methods and compositions for treating diseases mediated by transglutaminase activity
BR9604882A (en) Combination therapy of anti-biotin conversion enzyme inhibitor and amount of reduced side effect of aldosterone antagonist for the treatment of cardiovascular disease
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
CA2136841A1 (en) Novel Piperidyl Amides, Sulfonamides and Sulfoxamides as Inhibitors of Cholesterol Biosynthesis
ZA943610B (en) Oligopeptides derived from c-reactive protein fragments
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
ATE197645T1 (en) IMMUNOENZYMATIC CONJUGATE, PRODUCTION METHOD THEREOF AND USES
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
AU3356000A (en) L-arginine based formulations for treating diseases and methods of using same
WO2000038690A3 (en) Prostaglandin e agonists for treatment of dry eye